On August 5, 2026, the US FDA approved mFLUSIVA (mRNA-1010), Moderna’s mRNA based influenza vaccine, making it the first flu shot built on mRNA technology to reach approval anywhere in the world. For adults 50 and older, and especially for anyone managing chronic conditions like diabetes, hypertension, or heart disease, this approval raises real questions: how does an mRNA flu vaccine work, how well does it protect against flu, and what does this mean for flu prevention going forward, including for patients in India who may be asking about it. This article breaks down what mFLUSIVA is, what the trial data shows, and what to know about flu vaccination this season.
Key Takeaways
• mFLUSIVA (mRNA-1010) is the world’s first mRNA based influenza vaccine, approved by the FDA on August 5, 2026 for adults 50 years and older.
• It received full approval for adults aged 50 to 64 and accelerated approval for adults 65 and older, with a confirmatory safety study required for the older age group.
• In its pivotal FLUENT trial of more than 40,000 adults, mFLUSIVA showed a relative vaccine efficacy of 26.6% compared with a standard dose flu vaccine, and 27.4% in adults 65 and older.
• The vaccine is trivalent, targeting influenza A (H1N1 and H3N2) and influenza B strains matched to the 2026-2027 flu season.
• Because mRNA vaccines can be manufactured faster than traditional egg based flu vaccines, this technology may allow quicker strain matching in future flu seasons.
• Side effects were generally similar to other flu vaccines but occurred at a somewhat higher rate, including fatigue, joint pain, and muscle aches, and ongoing safety monitoring is planned through 2031.
What Is mFLUSIVA and How Is It Different From a Regular Flu Shot?
mFLUSIVA works on the same messenger RNA (mRNA) platform used in mRNA COVID-19 vaccines, rather than the older methods used to make traditional flu shots. Conventional influenza vaccines are typically grown in eggs or cell cultures using an inactivated form of the virus, a process that can take months and depends on how well the manufacturing strain matches the actual circulating flu virus.
An mRNA flu vaccine instead uses a small piece of genetic code that instructs the body’s own cells to briefly produce a harmless piece of viral protein, which trains the immune system to recognize and fight the real virus if exposed later. This manufacturing approach is notably faster than traditional methods, which is one of the main reasons researchers and public health officials are interested in mRNA technology for future flu seasons, particularly if a new or unexpected strain emerges.
What Does the Clinical Trial Data Show About mFLUSIVA’s Effectiveness?
The FDA’s approval of mFLUSIVA was based on results from the FLUENT trial, a large phase 3 study that compared the mRNA vaccine directly against a standard dose licensed influenza vaccine.
• The trial enrolled more than 40,000 adults aged 50 and older, randomly assigned to receive either mFLUSIVA or a standard dose comparator flu vaccine.
• Over a median follow up of about six months, mFLUSIVA demonstrated a relative vaccine efficacy of 26.6% compared with the standard dose vaccine in the overall study population.
• In adults 65 and older, a group that carries a disproportionate share of flu related hospitalizations and deaths, efficacy was measured at 27.4% relative to the comparator.
• These results met the study’s prespecified criteria for statistical superiority over a standard flu vaccine, which supported the FDA’s decision to approve it.
Full trial data and safety information are available in the FDA’s official approval letter and in coverage from Healthcare Dive.
Does a 27% Relative Efficacy Improvement Mean the Vaccine Prevents 27% of All Flu Cases?
Not quite, and this is a common point of confusion. Relative vaccine efficacy compares how a new vaccine performs against an existing, already effective vaccine, not against no vaccination at all. A relative efficacy of 26.6% to 27.4% means mFLUSIVA prevented meaningfully more confirmed flu illness than the standard dose comparator vaccine, which itself already provides substantial protection compared with being unvaccinated. In practical terms, this represents an incremental improvement over an already effective option, not a vaccine that is only modestly protective on its own.
Who Is mFLUSIVA Approved For, and Who Should Consider It?
mFLUSIVA’s approval is specifically defined by age, and understanding this is important for anyone deciding on flu vaccination this season.
• Adults aged 50 to 64 have full FDA approval to receive mFLUSIVA as a seasonal influenza vaccine option.
• Adults 65 and older can also receive it under accelerated approval, though this age group’s approval is contingent on results from an ongoing confirmatory postmarketing trial comparing it with a high dose flu vaccine.
• This age group matters clinically because, according to data cited in FDA review documents, adults 65 and older accounted for 57% of flu related hospitalizations and 71% of flu related deaths in a recent US flu season.
• mFLUSIVA is not yet approved for younger adults or children, so it does not currently replace standard flu vaccines for those age groups.
Should Older Adults Wait for mFLUSIVA Instead of Getting a Standard Flu Shot This Season?
No. Public health experts have been clear on this point: the most important decision for the 2026-2027 flu season is to get an appropriate flu vaccine promptly, rather than delaying vaccination while waiting for a specific product to become widely available. mFLUSIVA adds a new, promising option to the existing lineup of effective flu vaccines, including high dose and adjuvanted vaccines already used for older adults, but experts note it is still early to call it clearly superior to those established options, since longer term real world data is still being collected.
What Side Effects and Safety Considerations Come With mFLUSIVA?
As with any vaccine, mFLUSIVA’s safety profile is an important part of the conversation, particularly since it uses a newer technology platform for flu prevention.
• The most commonly reported side effects in trials were fatigue, joint pain, and muscle aches, consistent with reactions seen after other mRNA vaccines such as the COVID-19 vaccines.
• These reactions occurred somewhat more frequently with mFLUSIVA than with the standard dose comparator vaccine in the FLUENT trial.
• No new or serious safety signals were identified by either Moderna or FDA reviewers during the review process.
• As a condition of the accelerated approval in adults 65 and older, Moderna is required to conduct a post-authorization safety study monitoring for rare events, including myocarditis, pericarditis, and Guillain-Barré syndrome, with a final report expected by the end of 2031.
Is mFLUSIVA Available in India, and What Should Indian Patients Know?
mFLUSIVA’s approval is currently limited to the United States, where Moderna expects initial doses to be available ahead of the 2026-2027 flu season. The vaccine is also under regulatory review in Europe, Canada, and Australia, with additional country submissions planned. For patients in India, this means mFLUSIVA is not yet an available option, but it reflects a broader global shift toward mRNA based vaccine technology that may eventually expand to other markets and other diseases.
What to avoid: Don’t delay getting a standard, locally available flu vaccine while waiting for mRNA options to arrive in your country, especially if you are over 50 or manage a chronic condition such as diabetes, hypertension, or heart disease. Don’t assume a “better” vaccine elsewhere changes what you should do this season. The available flu vaccine now is almost always better protection than no vaccine at all.
How Is Seasonal Influenza Diagnosed and Differentiated From Other Fevers?
Because flu symptoms can overlap with other common infections, especially during monsoon and post-monsoon months in India, proper evaluation matters.
• Clinical evaluation of symptoms such as fever, body aches, sore throat, cough, and fatigue, alongside their pattern of onset.
• Rapid influenza diagnostic tests or PCR based testing, when available, to confirm influenza infection.
• Differentiation from other seasonal illnesses such as dengue, malaria, and viral fevers, which can present similarly in the first few days.
• Risk assessment for complications, particularly in older adults, pregnant women, and people with underlying chronic conditions.
Early signs worth flagging to your doctor include sudden high fever, body aches, sore throat, dry cough, and fatigue, especially if you are over 50 or manage a chronic health condition.
When Should You Seek Medical Care for Flu Symptoms?
Consult Dr. Krishna Prabhakar’s clinic if you or a family member is experiencing:
• Sudden fever with body aches, sore throat, or persistent cough
• Uncertainty about which seasonal illness (flu, dengue, or another viral fever) matches your symptoms
• Questions about flu vaccination timing or options available in India
• Chronic conditions such as diabetes, hypertension, or heart disease alongside flu-like symptoms
Call +91 98852 32820 or book an appointment online to schedule a consultation.
Certain symptoms need urgent medical attention rather than a routine visit: difficulty breathing or shortness of breath, persistent chest pain or pressure, confusion, severe or persistent vomiting, or symptoms that improve and then suddenly worsen. If any of these occur, seek emergency care immediately.
Medically Reviewed & Approved By
Dr. K. Krishna Prabhakar
Director, Department of Internal Medicine & Critical Care, Renova Century Hospitals, Banjara Hills, Hyderabad
Dr. Krishna Prabhakar has more than two decades of clinical experience managing infectious diseases, critical care, and complex medical conditions. This article has been medically reviewed for accuracy as of September 2026 and reflects the most current FDA approval information available at the time of publication.
Medical References
2. Pharmacy Times. FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine. August 2026.
3. Healthcare Dive. FDA Approves Moderna’s mRNA Flu Vaccine. Published August 6, 2026.
4. Harvard Health Publishing. FDA Approves First mRNA-Based Flu Vaccine.
5. PharmExec. FDA Approves Moderna’s mRNA-Based Flu Vaccine.
6. Vaccine Advisor. Moderna’s mFlusiva Approved as First mRNA-Based Influenza Vaccine. August 11, 2026.
Frequently Asked Questions
1. What is mFLUSIVA and when was it approved?
mFLUSIVA (mRNA-1010) is Moderna’s mRNA based influenza vaccine, the first flu vaccine built on mRNA technology. It was approved by the FDA on August 5, 2026 for adults 50 years and older.
2. How is an mRNA flu vaccine different from a traditional flu shot?
Traditional flu vaccines use an inactivated virus grown in eggs or cell culture, while mRNA vaccines use a piece of genetic code that instructs the body to produce a harmless viral protein, training the immune system faster and with quicker manufacturing turnaround.
3. How effective is mFLUSIVA compared with a standard flu vaccine?
In its pivotal trial, mFLUSIVA showed a relative vaccine efficacy of 26.6% overall and 27.4% in adults 65 and older compared with a standard dose flu vaccine, meeting the criteria for statistical superiority.
4. Who is eligible to receive mFLUSIVA?
Adults aged 50 to 64 have full FDA approval, and adults 65 and older can receive it under accelerated approval, pending results from an ongoing confirmatory safety study.
5. What are the side effects of the new mRNA flu vaccine?
The most common side effects reported were fatigue, joint pain, and muscle aches, occurring somewhat more often than with standard flu vaccines, though no new serious safety concerns were identified.
6. Is mFLUSIVA available in India?
Not currently. The approval is limited to the United States for now, with regulatory review ongoing in Europe, Canada, and Australia. Availability in India has not yet been announced.
7. Should older adults wait for mFLUSIVA instead of getting their regular flu shot?
No. Health experts recommend getting an appropriate flu vaccine promptly for the current season rather than delaying vaccination while waiting for a specific product to become available.
8. Why does mRNA technology matter for future flu vaccines?
mRNA vaccines can be manufactured faster than traditional egg based flu vaccines, which may allow quicker responses to newly emerging or mismatched flu strains in future seasons.
9. Does mFLUSIVA replace flu vaccines for younger adults or children?
No. Its current approval is limited to adults 50 and older, so standard flu vaccines remain the appropriate choice for younger adults and children.
10. How can I tell if my symptoms are flu, dengue, or another viral fever?
Flu, dengue, and other viral fevers can look similar in the first few days, so clinical evaluation and, when appropriate, diagnostic testing are important to confirm the cause, especially if fever persists or worsens.